Press releases
- REGENXBIO to Participate in Upcoming Investor Conferences
- REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
- REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
- REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
- REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
- REGENXBIO Announces Proposed Public Offering of Common Stock
- REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
More ▼
Key statistics
On Friday, Regenxbio Inc (RB0:FRA) closed at 12.80, 14.29% above the 52 week low of 11.20 set on Jan 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.80 |
---|---|
High | 12.80 |
Low | 12.80 |
Bid | 13.20 |
Offer | 13.30 |
Previous close | 12.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 49.26m |
Free float | 45.74m |
P/E (TTM) | -- |
Market cap | 706.82m USD |
EPS (TTM) | -5.88 USD |
Data delayed at least 15 minutes, as of May 31 2024 07:03 BST.
More ▼